Screener
Adaptive Biotechnologies ADPT Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Adaptive Biotechnologies’s reported figures.
Based on the most recent quarter.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
FAQ
- What is Adaptive Biotechnologies's debt-to-equity?
- Adaptive Biotechnologies (ADPT) reported debt-to-equity of 1× in Q1 2026.
- How has Adaptive Biotechnologies's debt-to-equity changed year-over-year?
- Adaptive Biotechnologies's debt-to-equity decreased by 16.9% year-over-year, from 1.2× to 1×.
- What is the long-term trend for Adaptive Biotechnologies's debt-to-equity?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's debt-to-equity has grown at a 46.0% compound annual growth rate (CAGR), from 0.1× to 1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Adaptive Biotechnologies's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude